A light exposure tracker designed to improve the circadian entrainment for Alzheimer Disease patients

一种光暴露跟踪器，旨在改善阿尔茨海默病患者的昼夜节律变化

• 批准号: 10707191
• 负责人: Erik Page
• 金额: $ 122.97万
• 依托单位: BLUE IRIS LABS, INC.
• 依托单位国家: 美国
• 财政年份: 2018
• 资助国家: 美国
• 起止时间: 2018-09-15 至 2024-08-31
• 项目状态: 已结题
• 来源: https://reporter.nih.gov/project-details/10707191
• 关键词: Address; Aging; Agitation; Alzheimer' s Disease; Alzheimer' s disease patient; Alzheimer' s disease related dementia; Area; Assessment tool; Automation; Caregivers; Cellular Phone; Characteristics; Circadian Dysregulation; Circadian Rhythms; Clinical Trials; Cognition; Companions; Controlled Environment; Darkness; Data; Data Collection; Data Storage and Retrieval; Dementia; Development; Devices; Disease; Elderly; Exposure to; Eye; Family; Feedback; Future; Goals; Health; Home; Human; Individual; Industry; Infrastructure; Internet; Intervention; Knowledge; Laboratories; Laboratory Study; Life; Light; Lighting; Maps; Measurement; Measures; Melatonin; Monitor; Moods; Neural Pathways; Neurosecretory Systems; Patients; Pattern; Personal Satisfaction; Persons; Phase; Phototherapy; Population; Process; Recommendation; Recording of previous events; Research; Research Personnel; Retinal Photoreceptors; Risk Reduction; Scientist; Sleep; Sleep Disorders; Small Business Innovation Research Grant; System; Technology; Testing; United States National Institutes of Health; Visualization; Wakefulness; Work; alertness; circadian; circadian pacemaker; cognitive testing; cohort; commercialization; cost effective; dashboard; design; digital; effectiveness testing; experience; exposed human population; field study; improved; improvement on sleep; interest; light intensity; mild cognitive impairment; negative affect; novel; response; sleep quality; success; tool; wireless

Project Summary The NIH has recognized the importance of circadian rhythms and sleep in Alzheimer’s disease (AD) and related dementias (ADRD) progression, recently releasing a Notice of Special Interest titled “Sleep Disorders and Circadian Clock Disruption in Alzheimer’s Disease and other Dementias of Aging.” The NIH has also noted that improving sleep quality is among the few interventions that people can take to reduce the risk of developing AD/ADRD later in life. Light therapy has shown great promise as a non-pharmacological treatment in helping to regulate sleep and in improving cognition in older adults with AD/ADRD. Perhaps not surprisingly given our evolutionary history, studies in this area can be simply summarized as: bright days and dark nights are beneficial for human health generally and AD/ADRD health specifically. Studies have demonstrated that daytime light exposure can consolidate and increase nighttime sleep efficiency, while also increasing daytime wakefulness and reducing evening agitation in AD/ADRD patients. But critical knowledge gaps exist, including information on the light exposure humans typically experience—at both individual and population levels—and how these vary from optimal light exposure patterns. Also missing are tools to collect these data and tools for individuals, researchers, and caregivers to monitor and control light exposure. In order to address these gaps, researchers have developed a novel, cost-effective, battery-powered light spectrometer which can measure circadian light characteristics and be discreetly mounted to walls or used as a wearable. This networked device provides continuous, remote data collection and storage, allowing interested parties to easily monitor circadian lighting conditions and adjust their lighting as needed. This project would build on these researcher-oriented tools and technologies to commercialize a new consumer- oriented version of this light exposure tracking system targeting patients with mild cognitive impairment (MCI) or early stage Alzheimer’s disease still living at home. Light exposure data collected by these systems would be used to provide actional recommendations and/or automations to improve circadian entrainment and overall health of AD/ADRD patients. The work proposed here will focus on the development of a new light exposure tracker, companion apps, and dashboards that gather much of the same detailed lighting data as the researcher- oriented device, but present these data in ways that are understandable and helpful for people with AD/ADRD and their caregivers. Integrations with related connected products, such as sleep trackers and smart lamps, will also be investigated. A clinical trial is proposed that includes both MCI and AD/ADRD patients living at home. The trial will characterize the light exposure that these cohorts experience and test a variety of interventions intended to bring their light exposure patterns more in line with patterns known to support circadian health.

项目摘要 NIH认识到昼夜节律和睡眠在阿尔茨海默氏病（AD）和相关的重要性 痴呆症（ADRD）的进展，最近发布了特殊兴趣的通知，标题为“睡眠障碍和 昼夜节律时钟破坏了阿尔茨海默氏病和其他衰老的痴呆症。” NIH还指出， 改善睡眠质量是人们可以采取的少数干预措施之一来降低发展的风险 广告/阿德德之后的生活。轻度疗法在帮助方面表现出了巨大的希望 调节睡眠并改善AD/ADRD老年人的认知。也许毫不奇怪 进化史，可以简单地总结在这一领域的研究：明亮的日子和黑暗的夜晚是有益的 对于人类健康，通常专门针对人类健康和AD/ADRD健康。研究证明了白天的光 暴露可以巩固并提高夜间睡眠效率，同时增加白天的清醒和 减少AD/ADRD患者的夜间搅动。但是存在关键的知识差距，包括有关 轻曝光人类通常会在个人和人口水平上体验到这些变化 从最佳的光曝光模式。还缺少的是为个人收集这些数据和工具的工具， 研究人员和护理人员监视和控制光线暴露。为了解决这些差距，研究人员 已经开发了一种新颖的，具有成本效益的电池供电光谱仪，可以测量昼夜节律 特征并谨慎地安装在墙壁上或用作可穿戴设备。该网络设备提供 连续的，远程数据收集和存储 条件并根据需要调整照明。 该项目将以这些面向研究人员的工具和技术为基础，以使新的消费者商业化 - 这种轻曝光跟踪系统的定向版本针对轻度认知障碍患者（MCI） 或阿尔茨海默氏病早期仍住在家里。这些系统收集的光暴露数据将是 用于提供积极的建议和/或自动化，以改善昼夜节目的入口和整体 AD/ADRD患者的健康。这里提出的工作将重点放在开发新的光曝光 跟踪器，伴侣应用程序和仪表板收集与研究人员相同的详细照明数据 定向设备，但以对AD/ADRD的人来说是可以理解且有帮助的方式呈现这些数据 和他们的照顾者。与相关连​​接的产品（例如睡眠跟踪器和智能灯）集成，将 也可以调查。提出了一项临床试验，其中包括居住在家中的MCI和AD/ADRD患者。 该试验将表征这些同类群体经历并测试各种干预措施的光暴露 旨在使其光线暴露方式更加符合支持昼夜节律的已知模式。